MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study

• Status: Recruiting
• Trial end date: 2021-05-10
• Target enrollment: 204
• Participant gender: All

Summary

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MedImmune LLC
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Fluorouracil; Gemcitabine; Oxaliplatin; Paclitaxel

Criteria

Inclusion Criteria:

1. Age ≥ 18

2. Written and signed informed consent must be obtained

3. ECOG Performance Status 0 or 1

4. Weight ≥ 35 kg

5. Subjects must have histologically or cytologically, confirmed pancreatic adenocarcinoma:

Cohort A: Subjects with previously untreated metastatic pancreatic adenocarcinoma (1st line metastatic disease) not previously treated with systemic therapies.

Cohort B: Subjects with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy (without exposure to 5-FU, capecitabine, oxaliplatin) 2nd line metastatic disease

6. Subjects must have at least 1 measurable lesion according to RECIST v1.1

7. All subjects must consent to providing archival tumor specimens

Exclusion Criteria:

1. Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment.

2. Prior receipt of any immune-related therapy

3. Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed

4. Subjects with a history of venous thrombosis within the past 3 months

5. Subjects with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 3 months prior to start of treatment

6. Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment

7. Other invasive malignancy within 2 years.

8. Any history of leptomeningeal disease or cord compression.

9. Current or prior use of immunosuppressive medication within 14 days prior to the first dose